Drugs / IBI321
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05172856 | Mar 2022 → Jun 2023 | — | Innovent Biologics (Suzhou) Co. Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04911881 | Jun 2021 → Feb 2023 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04911894 | Jun 2021 → Jan 2023 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-07-26 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors innoventbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI321 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04911881 ↗ |
| Route | Intravenous | “IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.” NCT04911881 ↗ |